Company profile: Aera Therapeutics
1.1 - Company Overview
Company description
- Provider of a proprietary protein nanoparticle (PNP) delivery platform based on human proteins to deliver genetic medicines across modalities and therapeutic areas, and a therapeutic enzyme platform with novel, compact, programmable gene-editing enzymes to overcome packaging and delivery challenges in gene therapy.
Products and services
- Programmable Gene Editing Enzymes: Compact enzymes engineered to enable precise gene editing and to overcome packaging and delivery constraints in gene therapy programs, featuring programmable activity
- Protein Nanoparticle (PNP) Delivery Platform: Proprietary, human-protein-based platform that delivers genetic medicines across diverse modalities and therapeutic areas using engineered protein nanoparticles
- Therapeutic Enzyme Platform: Architects a suite of novel, programmable gene-editing enzymes designed to surmount packaging and delivery challenges inherent to gene therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aera Therapeutics
SARcode Bioscience
HQ: United States
Website
- Description: Provider of a novel class of small-molecule LFA-1 (CD11a/CD18; αLβ2) antagonists in development as topical agents to address significant unmet medical needs in ophthalmology, dermatology and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SARcode Bioscience company profile →
Principia Biopharma
HQ: United States
Website
- Description: Provider of pre-clinical discovery and development of differentiated oral small-molecule therapies for inflammatory and autoimmune diseases and cancer, addressing significant unmet medical needs in immunology and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Principia Biopharma company profile →
Genome Diagnostics
HQ: The Netherlands
Website
- Description: Provider of in vitro diagnostic tests and services, molecular diagnostic kits, analysis software, and education for transplantation and companion diagnostics. Delivers sequencing-based, high-resolution HLA typing for Sanger and NGS, NGSgo workflows, Oxford Nanopore solutions (NGS-Pronto, NGS-Turbo), NGSengine-Turbo software, and chimerism monitoring assays and software (NGStrack, TRKengine).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genome Diagnostics company profile →
Bryn Pharma
HQ: United States
Website
- Description: Provider of nasal-based epinephrine for anaphylaxis, including NDS1C, a needle-free, easy-to-use epinephrine nasal spray for the treatment of anaphylaxis. Also offers a Clinical Development Program focused on demonstrating the pharmacokinetic parameters and safety of NDS1C compared to the 0.3 mg IM epinephrine autoinjector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bryn Pharma company profile →
NodThera
HQ: United Kingdom
Website
- Description: Provider of NLRP3 inflammasome inhibitor therapeutics targeting inflammatory and neuroinflammatory diseases, including brain-penetrant candidates. Lead asset NT-0796 is in Phase Ib/IIa for Parkinson’s disease and cardiovascular risk in obese patients; NT-0249 is optimized for low-dose chronic inflammatory therapy, with additional CNS and peripheral candidates under development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NodThera company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aera Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aera Therapeutics
2.2 - Growth funds investing in similar companies to Aera Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aera Therapeutics
4.2 - Public trading comparable groups for Aera Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →